OCULAR THERAPEUTIX, INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
OCULAR THERAPEUTIX, INC (OCUL) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $67.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $67.20M, a 61.89% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $41.51M, a 116.30% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $19.19M, a 12.41% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $21.91M, a 11.68% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $67.20M 10-K · filed 2026-02-05 |
| 2024-12-31 | $41.51M 10-K · filed 2026-02-05 |
| 2023-12-31 | $19.19M 10-K · filed 2026-02-05 |
| 2022-12-31 | $21.91M 10-K · filed 2025-03-03 |
| 2021-12-31 | $19.62M 10-K · filed 2024-03-11 |
| 2020-12-31 | $17.96M 10-K · filed 2023-03-06 |
| 2018-12-31 | $16.62M 10-K · filed 2019-03-07 |
| 2017-12-31 | -$2.51M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |